Acumen Pharmaceuticals, Inc.
ABOSNASDAQHealthcare● Active
$2.27
+$0.10(+4.52%)
Market Cap$137386529
P/E Ratio—
52W High$3.6
52W Low$1.05
Acumen Pharmaceuticals, Inc. (ABOS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ABOS · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$0.33
Est. -$0.40 · +18.1%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▲ Beat EPS✓ 3-Quarter EPS Beat Streak
ABOS reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.39 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 12, 2026 | -$0.40 | -$0.33 | +18.1% | — | — | — |
| ▲ Q1 FY2026 | Mar 26, 2026 | -$0.50 | -$0.41 | +18.0% | — | — | — |
| ▲ Q4 FY2025 | Nov 12, 2025 | -$0.63 | -$0.44 | +30.2% | — | — | — |
| ▼ Q3 FY2025 | Aug 12, 2025 | -$0.54 | -$0.68 | -25.9% | — | — | — |
| ▲ Q2 FY2025 | May 13, 2025 | -$0.56 | -$0.48 | +14.3% | — | — | — |
| ▼ Q1 FY2025 | Mar 27, 2025 | -$0.47 | -$0.62 | -31.9% | — | — | — |
| ▼ Q4 FY2024 | Nov 12, 2024 | -$0.36 | -$0.50 | -38.9% | — | — | — |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.39
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Beat
EPS Actual
-$0.33
EPS Est.
-$0.40
EPS Surpr.
+18.1%
Revenue
—
Q1 FY2026
Mar 26, 2026Beat
EPS Actual
-$0.41
EPS Est.
-$0.50
EPS Surpr.
+18.0%
Revenue
—
Q4 FY2025
Nov 12, 2025Beat
EPS Actual
-$0.44
EPS Est.
-$0.63
EPS Surpr.
+30.2%
Revenue
—
Q3 FY2025
Aug 12, 2025Miss
EPS Actual
-$0.68
EPS Est.
-$0.54
EPS Surpr.
-25.9%
Revenue
—
Q2 FY2025
May 13, 2025Beat
EPS Actual
-$0.48
EPS Est.
-$0.56
EPS Surpr.
+14.3%
Revenue
—
Q1 FY2025
Mar 27, 2025Miss
EPS Actual
-$0.62
EPS Est.
-$0.47
EPS Surpr.
-31.9%
Revenue
—
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
-$0.50
EPS Est.
-$0.36
EPS Surpr.
-38.9%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.24 | $-0.24 | $-0.24 | 1 |
| Q3 FY2027 | $-0.23 | $-0.23 | $-0.23 | 1 |
| Q2 FY2027 | $-0.22 | $-0.22 | $-0.22 | 1 |
| Q1 FY2027 | $-0.23 | $-0.23 | $-0.23 | 1 |
| Q4 FY2026 | $-0.37 | $-0.37 | $-0.37 | 1 |
| Q3 FY2026 | $-0.38 | $-0.38 | $-0.38 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 12, 2026 | +18.1% | $2.57 | $2.48 | -3.50% |
| ▲ Q1 FY2026 | Mar 26, 2026 | +18.0% | $2.63 | $2.55 | -3.04% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +30.2% | $1.97 | $1.95 | -1.02% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -25.9% | $1.42 | $1.26 | -11.27% |
| ▲ Q2 FY2025 | May 13, 2025 | +14.3% | $1.05 | $1.05 | +0.00% |
| ▼ Q1 FY2025 | Mar 27, 2025 | -31.9% | $1.16 | $1.23 | +6.03% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -38.9% | $3.22 | $2.68 | -16.77% |
| ▼ Q3 FY2024 | Aug 13, 2024 | -21.4% | $2.56 | $2.77 | +8.20% |
Q2 FY2026-3.50%
Report Date
May 12, 2026
EPS Beat/Miss
+18.1%
Price Before
$2.57
Price After
$2.48
Q1 FY2026-3.04%
Report Date
Mar 26, 2026
EPS Beat/Miss
+18.0%
Price Before
$2.63
Price After
$2.55
Q4 FY2025-1.02%
Report Date
Nov 12, 2025
EPS Beat/Miss
+30.2%
Price Before
$1.97
Price After
$1.95
Q3 FY2025-11.27%
Report Date
Aug 12, 2025
EPS Beat/Miss
-25.9%
Price Before
$1.42
Price After
$1.26
Q2 FY2025+0.00%
Report Date
May 13, 2025
EPS Beat/Miss
+14.3%
Price Before
$1.05
Price After
$1.05
Q1 FY2025+6.03%
Report Date
Mar 27, 2025
EPS Beat/Miss
-31.9%
Price Before
$1.16
Price After
$1.23
Q4 FY2024-16.77%
Report Date
Nov 12, 2024
EPS Beat/Miss
-38.9%
Price Before
$3.22
Price After
$2.68
Q3 FY2024+8.20%
Report Date
Aug 13, 2024
EPS Beat/Miss
-21.4%
Price Before
$2.56
Price After
$2.77
Avg Beat Reaction-1.89%
Avg Miss Reaction-3.45%
Beat Rate4 / 8 quarters
Largest Move-16.77% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ABOS ends December
Acumen Pharmaceuticals, Inc. (ABOS) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.33 — beating the analyst consensus of $-0.40 by +18.1%. ABOS has beaten EPS estimates for 3 consecutive quarters. The next ABOS earnings date is expected around September 1, 2026.
Each quarter, investors track ABOS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ABOS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ABOS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ABOS earnings · 5 questionsAcumen Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. ABOS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ABOS historically reports after market close (AMC).
ABOS earnings datewhen is ABOS earningsABOS next earnings datewhen does ABOS report earningsABOS earnings calendar
▸ Source: FMP · Acumen Pharmaceuticals, Inc. SEC filings · US GAAP · Acumen Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026